Business

Accord Transformer & Switchgear Limited Files RHP; SME IPO to Open on February 23, 2026

Feb 19, 2026

PNN
Mumbai (Maharashtra) [India], February 19: Accord Transformer & Switchgear Limited, a manufacturer of transformers, switchgear and customised power solutions, has filed its Red Herring Prospectus (RHP) dated February 16, 2026 with the Registrar of Companies, Haryana, in connection with its proposed SME initial public offering (IPO).
The IPO comprises a fresh issue of up to 55,62,000 equity shares of face value ₹10 each through the book-building route.
Out of the total issue of up to 55,62,000 equity shares, up to 2,82,000 shares are reserved for the Market Maker. The net issue of up to 52,80,000 shares will be allocated as follows:
not more than 50% to Qualified Institutional Buyers, not less than 15% to Non-Institutional Investors and not less than 35% to Individual Investors.
The issue will open for subscription on Monday, February 23, 2026 and close on Wednesday, February 25, 2026, with the equity shares proposed to be listed on the BSE SME platform. The anchor investor portion shall open and close on Friday, February 20, 2026.
IPO Highlights
- Fresh Issue: up to 55,62,000 equity shares
- Face Value: ₹10 per share
- Issue Type: 100% book-built SME IPO
- Listing: BSE SME
- Promoters: Mr. Pradeep Kumar Verma & Mrs. Shalini Singh
- Book Running Lead Manager: GYR Capital Advisors Pvt. Ltd.
The price band and bid lot will be decided by the company in consultation with the Book Running Lead Manager and announced prior to issue opening.
(ADVERTORIAL DISCLAIMER: The above press release has been provided by PNN. ANI will not be responsible in any way for the content of the same.)

More news

Indigenous CAR-T Therapy Signals New Phase for India's Cancer Care and Biotech Manufacturing

New Delhi [India], February 19: When Ms. Arora's cancer returned, the emotional weight of relapse was immediate. Having already undergone standard lines of treatment for non-Hodgkin's lymphoma (NHL) after her diagnosis in 2022, she now faced a narrower set of options--each complex, each uncertain. "I remember feeling that the ground had shifted again," she says. "But my medical team walked me through the available options, and we decided to move forward with an indigenous CAR-T therapy." Today, her story forms part of a broader shift unfolding in India's oncology ecosystem--one marked not just by clinical innovation, but by homegrown scientific capability.

Feb 19, 2026